tiprankstipranks
Alkermes (ALKS)
NASDAQ:ALKS
US Market
ALKS
Alkermes
RESEARCH TOOLSreports
Want to see ALKS full AI Analyst Report?

Alkermes (ALKS) Stock Forecast & Price Target

631 Followers
See the Price Targets and Ratings of:

ALKS Analyst Ratings

Strong Buy
15Ratings
Strong Buy
12 Buy
3 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Alkermes
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$46.25
▲(33.94% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $46.25 with a high forecast of $58.00 and a low forecast of $42.00. The average price target represents a 33.94% change from the last price of $34.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","42":"$42","59":"$59","33.5":"$33.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33.5,42,50.5,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.38,35.27384615384616,37.16769230769231,39.06153846153846,40.95538461538462,42.84923076923077,44.74307692307693,46.63692307692308,48.53076923076923,50.424615384615386,52.31846153846154,54.21230769230769,56.106153846153845,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.38,34.370000000000005,35.36,36.35,37.34,38.33,39.32,40.31,41.3,42.29,43.28,44.269999999999996,45.26,{"y":46.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.38,34.043076923076924,34.706153846153846,35.36923076923077,36.0323076923077,36.69538461538462,37.35846153846154,38.02153846153846,38.684615384615384,39.347692307692306,40.01076923076923,40.673846153846156,41.33692307692308,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.985,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.05,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$58.00Average Price Target$46.25Lowest Price Target$42.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on ALKS
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$43→$44
Buy
27.43%
Upside
Reiterated
05/06/26
Alkermes (ALKS) Receives a Buy from Wells Fargo
Needham Analyst forecast on ALKS
Ami Fadia
Needham
Needham
$45→$50
Buy
44.80%
Upside
Assigned
05/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on ALKS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$46→$43
Hold
24.53%
Upside
Reiterated
05/06/26
H.C. Wainwright Sticks to Its Hold Rating for Alkermes (ALKS)
UBS Analyst forecast on ALKS
Ashwani Verma
UBS
UBS
$42→$48
Buy
39.01%
Upside
Reiterated
05/06/26
Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS
TD Cowen Analyst forecast on ALKS
Joseph Thome
TD Cowen
TD Cowen
$40→$42
Buy
21.63%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Tenaya Therapeutics (NASDAQ: TNYA)
RBC Capital Analyst forecast on ALKS
Leonid Timashev
RBC Capital
RBC Capital
$44
Buy
27.43%
Upside
Reiterated
05/05/26
RBC Capital Keeps Their Buy Rating on Alkermes (ALKS)
Mizuho Securities Analyst forecast on ALKS
Uy Ear
Mizuho Securities
Mizuho Securities
$53
Buy
53.49%
Upside
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Baxter International (BAX)
Piper Sandler Analyst forecast on ALKS
David Amsellem
Piper Sandler
Piper Sandler
$43
Buy
24.53%
Upside
Reiterated
04/13/26
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE)
Bank of America Securities Analyst forecast on ALKS
Jason Gerberry
Bank of America Securities
Bank of America Securities
―
Hold
―
Reiterated
04/09/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (NASDAQ: ALKS), ProQR (NASDAQ: PRQR) and Simulations Plus (NASDAQ: SLP)
Stifel Nicolaus Analyst forecast on ALKS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$30.15→$42
Buy
21.63%
Upside
Reiterated
04/04/26
Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)
Leerink Partners Analyst forecast on ALKS
Marc Goodman
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/31/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on ALKS
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$43
Buy
24.53%
Upside
Reiterated
03/11/26
Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)
Truist Financial Analyst forecast on ALKS
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on ALKS
Rudy Li
Wolfe Research
Wolfe Research
$45
Buy
30.32%
Upside
Initiated
02/23/26
Alkermes initiated with an Outperform at Wolfe ResearchAlkermes initiated with an Outperform at Wolfe Research
Jefferies Analyst forecast on ALKS
Akash Tewari
Jefferies
Jefferies
$58
Buy
67.97%
Upside
Reiterated
02/10/26
Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), Waters (NYSE: WAT) and Alkermes (NASDAQ: ALKS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on ALKS
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$43→$44
Buy
27.43%
Upside
Reiterated
05/06/26
Alkermes (ALKS) Receives a Buy from Wells Fargo
Needham Analyst forecast on ALKS
Ami Fadia
Needham
Needham
$45→$50
Buy
44.80%
Upside
Assigned
05/06/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on ALKS
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$46→$43
Hold
24.53%
Upside
Reiterated
05/06/26
H.C. Wainwright Sticks to Its Hold Rating for Alkermes (ALKS)
UBS Analyst forecast on ALKS
Ashwani Verma
UBS
UBS
$42→$48
Buy
39.01%
Upside
Reiterated
05/06/26
Alkermes price target raised to $48 from $42 at UBSAlkermes price target raised to $48 from $42 at UBS
TD Cowen Analyst forecast on ALKS
Joseph Thome
TD Cowen
TD Cowen
$40→$42
Buy
21.63%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS) and Tenaya Therapeutics (NASDAQ: TNYA)
RBC Capital Analyst forecast on ALKS
Leonid Timashev
RBC Capital
RBC Capital
$44
Buy
27.43%
Upside
Reiterated
05/05/26
RBC Capital Keeps Their Buy Rating on Alkermes (ALKS)
Mizuho Securities Analyst forecast on ALKS
Uy Ear
Mizuho Securities
Mizuho Securities
$53
Buy
53.49%
Upside
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Alkermes (ALKS), Baxter International (BAX)
Piper Sandler Analyst forecast on ALKS
David Amsellem
Piper Sandler
Piper Sandler
$43
Buy
24.53%
Upside
Reiterated
04/13/26
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE)
Bank of America Securities Analyst forecast on ALKS
Jason Gerberry
Bank of America Securities
Bank of America Securities
―
Hold
―
Reiterated
04/09/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (NASDAQ: ALKS), ProQR (NASDAQ: PRQR) and Simulations Plus (NASDAQ: SLP)
Stifel Nicolaus Analyst forecast on ALKS
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$30.15→$42
Buy
21.63%
Upside
Reiterated
04/04/26
Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)
Leerink Partners Analyst forecast on ALKS
Marc Goodman
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
03/31/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Cantor Fitzgerald Analyst forecast on ALKS
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$43
Buy
24.53%
Upside
Reiterated
03/11/26
Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)
Truist Financial Analyst forecast on ALKS
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/26/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on ALKS
Rudy Li
Wolfe Research
Wolfe Research
$45
Buy
30.32%
Upside
Initiated
02/23/26
Alkermes initiated with an Outperform at Wolfe ResearchAlkermes initiated with an Outperform at Wolfe Research
Jefferies Analyst forecast on ALKS
Akash Tewari
Jefferies
Jefferies
$58
Buy
67.97%
Upside
Reiterated
02/10/26
Analysts Offer Insights on Healthcare Companies: Personalis (NASDAQ: PSNL), Waters (NYSE: WAT) and Alkermes (NASDAQ: ALKS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

3 Months
xxx
Success Rate
12/16 ratings generated profit
75%
Average Return
+5.54%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.54% per trade.
1 Year
Paul MatteisStifel Nicolaus
Success Rate
15/16 ratings generated profit
94%
Average Return
+16.77%
Copying Paul Matteis's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +16.77% per trade.
2 Years
xxx
Success Rate
25/26 ratings generated profit
96%
Average Return
+18.36%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 96.15% of your transactions generating a profit, with an average return of +18.36% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
3
4
4
3
Buy
11
13
13
16
13
Hold
5
4
4
5
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
20
21
25
19
In the current month, ALKS has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 46.25.
Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is >-$0.01 with a range of -$0.18 to $0.25. The previous quarter’s EPS was -$0.40. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.
Next quarter’s earnings estimate for ALKS is >-$0.01 with a range of -$0.18 to $0.25. The previous quarter’s EPS was -$0.40. ALKS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $460.46M with a range of $436.00M to $488.40M. The previous quarter’s sales results were $392.91M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.
Next quarter’s sales forecast for ALKS is $460.46M with a range of $436.00M to $488.40M. The previous quarter’s sales results were $392.91M. ALKS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ALKS has Performed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?
Based on analyst ratings, Alkermes’s 12-month average price target is 46.25.
    What is ALKS’s upside potential, based on the analysts’ average price target?
    Alkermes has 33.94% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALKS a Buy, Sell or Hold?
          Alkermes has a consensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Alkermes’s price target?
            The average price target for Alkermes is 46.25. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $58.00 ,the lowest forecast is $42.00. The average price target represents 33.94% Increase from the current price of $34.53.
              What do analysts say about Alkermes?
              Alkermes’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of ALKS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.